These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31455314)

  • 1. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
    Masuka JT; Khoza S
    BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana.
    Dodoo AN; Renner L; van Grootheest AC; Labadie J; Antwi-Agyei KO; Hayibor S; Addison J; Pappoe V; Appiah-Danquah A
    Drug Saf; 2007; 30(4):347-56. PubMed ID: 17408311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018.
    Clothier HJ; Lawrie J; Lewis G; Russell M; Crawford NW; Buttery JP
    Commun Dis Intell (2018); 2020 Jun; 44():. PubMed ID: 32536336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].
    Sawadogo R; Ouoba J; Ilboudo D; Tchoumbi E; Lankoandé-Haro S; Fofana S; Sombié I; Samadoulougou S; Kirakoya-Samadoulougou F
    Sante Publique; 2024 Feb; 35(6):149-159. PubMed ID: 38388395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual report: surveillance of adverse events following immunisation in Australia, 2008.
    Menzies R; Mahajan D; Gold MS; Roomiani I; McIntyre P; Lawrence G
    Commun Dis Intell Q Rep; 2009 Dec; 33(4):365-81. PubMed ID: 20301966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of adverse events following immunisation: Australia, 2000-2002.
    Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D
    Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual report: Surveillance of adverse events following immunisation in Australia, 2005.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2006; 30(3):319-33. PubMed ID: 17120485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
    Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
    Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of adverse events following immunisation in Australia annual report, 2017.
    Dey A; Wang H; Quinn H; Hiam R; Wood N; Beard F; Macartney K
    Commun Dis Intell (2018); 2019 Jul; 43():. PubMed ID: 31315166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016.
    Mentzer D; Oberle D; Keller-Stanislawski B
    Euro Surveill; 2018 Apr; 23(17):. PubMed ID: 29717697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual report: surveillance of adverse events following immunisation in Australia, 2007.
    Lawrence G; Gold MS; Hill R; Deeks S; Glasswell A; McIntyre PB
    Commun Dis Intell Q Rep; 2008 Dec; 32(4):371-87. PubMed ID: 19374268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
    Masuka JT; Khoza S
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annual report: surveillance of adverse events following immunisation in Australia, 2004.
    Lawrence GL; Boyd I; McIntyre PB; Isaacs D
    Commun Dis Intell Q Rep; 2005; 29(3):248-62. PubMed ID: 16220860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annual report on surveillance of adverse events following immunisation in Australia, 2006.
    Lawrence GL; Aratchige PE; Boyd I; McIntyre PB; Gold MS
    Commun Dis Intell Q Rep; 2007 Sep; 31(3):269-82. PubMed ID: 17974219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of adverse events following immunisation in Australia, 2015.
    Dey A; Wang H; Quinn H; Cook J; Macartney K
    Commun Dis Intell Q Rep; 2017 Sep; 41(3):E260-E274. PubMed ID: 29720075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China.
    Hu Y; Li Q; Lin L; Chen E; Chen Y; Qi X
    Clin Vaccine Immunol; 2013 Feb; 20(2):211-7. PubMed ID: 23239804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022.
    Giang E; Xu Y; Naganathan T; Abraham N; Bawolak MT; Salim BS; Weeks A; Shaw A; Ogunnaike-Cooke S
    Can Commun Dis Rep; 2024 Jan; 50(1-2):16-24. PubMed ID: 38655243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.